EUCTR2017-000048-17-AT进行中（未招募）1 期
A trial comparing the effect and safety of insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 214
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •-Female, age at least 18 years at the time of signing informed consent
- •-Diagnosed with type 1 diabetes mellitus for at least 1 year prior to the day of screening
- •-Treated with multiple daily subcutaneous insulin injections or continuous subcutaneous insulin infusion (CSII) or inhaled insulin for at least 90 days prior to the day of screening
- •-The subject is planning to become pregnant within 12 months from randomisation and willing to undertake pre-pregnancy counselling or the subject is pregnant with an intrauterine singleton living foetus (gestational week 8 to 13 (+6 days)) without any observed anomalies at randomisation, confirmed by an ultrasound scan
- •- HbA1c at screening below or equal to 8.0% (64 mmol/mol) by central laboratory
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 214
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening
- •-Pregnant and having proteinuria as evaluated by urine protein-to-creatinine ratio above or equal to 300 mg/g in urine sample measured at screening
- •-Subject being treated or became pregnant with assistance of in vitro fertilisation or other medical infertility treatment
- •-Receipt of any concomitant medication contraindicated in pregnancy according to local label within 28 days before screening and between screening and randomisation for non-pregnant subjects and 28 days before conception and between conception and randomisation for pregnant subjects
- •-Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or pharmacologically dilated fundoscopy performed within the past 90 days prior to randomisation for non-pregnant subjects or within 28 days prior to randomisation for pregnant subjects
- •-History of severe hyperemesis gravidarum (requiring hospitalisation)
研究者
相似试验
进行中（未招募）
1 期
Research study comparing insulin degludec to insulin detemir, together with insulin aspart, in pregnant women with type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 21.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861EUCTR2017-000048-17-DKovo Nordisk A/S214
进行中（未招募）
1 期
Research study comparing insulin degludec to insulin detemir, together with insulin aspart, in pregnant women with type 1 diabetesMedDRA version: 20.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 1EUCTR2017-000048-17-GRovo Nordisk A/S300
进行中（未招募）
1 期
Research study comparing insulin degludec to insulin detemir, together with insulin aspart, in pregnant women with type 1 diabetesMedDRA version: 21.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 1EUCTR2017-000048-17-ITOVO NORDISK. S.P.A.300
进行中（未招募）
1 期
Research study comparing insulin degludec to insulin detemir, together with insulin aspart, in pregnant women with type 1 diabetesDiabetes Mellitus, Type 1EUCTR2017-000048-17-GBovo Nordisk A/S214
进行中（未招募）
1 期
Research study comparing insulin degludec to insulin detemir, together with insulin aspart, in pregnant women with type 1 diabetesDiabetes Mellitus, Type 1EUCTR2017-000048-17-IEovo Nordisk A/S214